Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Dr Reddy’s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization Gilead Sciences to fabricate and advertise remdesivir – a potential COVID-19 medication in 127 nations, including India.
According to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy’s Laboratories said in an announcement.
The organization will get innovation move from Gilead for assembling of the medication, it included.
Dr Reddy’s would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.
Remdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.